跳至主要内容
临床试验/EUCTR2012-004892-37-BE
EUCTR2012-004892-37-BE进行中(未招募)1 期

Acetylcysteine in patients with Sickle Cell Disease: Reducing the incidence of daily life pain in patients with sickle cell disease - NAC Trial

Academic Medical Center0 个研究点目标入组 140 人开始时间: 2014年10月21日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
140

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • -Age 12 years or older
  • -Sickle cell disease, either homozygous sickle cell disease (HbSS), HbSC sickle cell
  • disease, HbSß0 or HbSß+ thalassemia.
  • Genotype needs to be confirmed by high performance liquid chromatography.
  • -History of at least 1.0 painful crisis per year in the past 3 years.
  • A crisis will be defined here as a patient defined, painful, sickle cell related episode of at least 24 hours where a subject experienced significant impediments in his/her daily activities, and pain medication had to be taken. A visit to a medical facility is not obligatory in this definition.
  • -Written informed consent from patient/parent/guardian is given.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 30
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 90
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 20

排除标准

  • -Chronic blood transfusion or transfusion in the preceding 3 months
  • -Painful crisis in the last 4 weeks (with respect to the moment of inclusion).
  • A crisis will be defined as above; a patient defined, painful, sickle cell related episode of at least 24 hours where the subject experienced significant impediments in his/her daily activities, and pain medication had to be taken. A visit to a medical facility is not obligatory in this definition.
  • -Pregnancy, breast feeding or the desire to get pregnant in the following 7 months
  • -Known active gastric/duodenal ulcers
  • -Hydroxycarbamide (HC) treatment with unstable dose in the last 3 months or started on
  • HC shorter then 6 months prior to study.
  • -Known poor compliance in earlier trials regarding the completion of pain diaries.
  • -Insufficient compliance in run-in period.
  • Participants that do not show up for their follow-up visit without prior notice, that not bring
  • their diary or with less than 80% of the days in the pain diary filled in, will be excluded from participation in this trial and will not be randomized.

研究者

发起方
Academic Medical Center

相似试验

进行中(未招募)
1 期
Acetylcysteine in patients with Sickle Cell Disease: Reducing the incidence of daily life pain in patients with sickle cell diseaseSickle CellMedDRA version: 15.1Level: LLTClassification code 10040643Term: Sickle cell crisisSystem Organ Class: 100000004850
EUCTR2012-004892-37-NLAcademic Medical Center140
进行中(未招募)
不适用
Acetylcysteine in patients with Sickle Cell Disease: Reducing the incidence of daily life pain in patients with sickle cell diseaseMedDRA version: 17.1Level: LLTClassification code 10002077Term: Anaemia sickle cellSystem Organ Class: 100000004850MedDRA version: 17.1Level: LLTClassification code 10040643Term: Sickle cell crisisSystem Organ Class: 100000004851Sickle Cell Disease
EUCTR2012-004892-37-GBAcademic Medical Center, Department of Haematology, University of Amsterdam140
招募中
不适用
Acetylcysteine in Patients With Sickle Cell Disease (NAC).Sickle Cell DiseaseSickle Cell AnemiaPainful CrisisPainSikkelcel ziekteSikkelcel anemiePijnlijke crisePijn
NL-OMON28196Academic Medical Center, Amsterdam140
尚未招募
不适用
Acetylcysteine for Treatment of Sickle Cell Diseasesickle cell disease10018902
NL-OMON30544Academisch Medisch Centrum10
进行中(未招募)
不适用
Acetylcysteine for Treatment of Sickle Cell Disease - N-acetylcystein for Sickle Cell DiseasePatients homozygous for sickle cell diseaseMedDRA version: 8.1Level: LLTClassification code 10040644Term: Sickle cell disease
EUCTR2006-005889-40-NLAcademic Medical Centre10